ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $1.32M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
32% more capital invested
Capital invested by funds: $995K → $1.32M (+$321K)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $317K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$550K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$205K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$5.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$158K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$32K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$28.1K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$16.3K |
| 5 |
Morgan Stanley
New York
|
-$15.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $725K | +$550K | +27,310 | +213% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $363K | +$205K | +10,173 | +102% |
|
|
3
Jane Street
New York
| $213K | -$158K | -7,844 | -40% |
|
|
4
Simplex Trading
Chicago,
Illinois
| $6K | -$16.3K | -811 | -69% |
|
|
5
UBS Group
Zurich,
Switzerland
| $5K | -$28.1K | -1,397 | -84% |
|
|
CG
6
Cutler Group
San Francisco,
California
| $4K | +$5.3K | +263 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$32K | -1,535 | Closed |
|
|
8
Morgan Stanley
New York
| – | -$15.7K | -780 | -99% |
|
ZBIO Hedge Fund Activity: Q2 2018 in Review
7 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q2 2018, worth a combined $1.32M — up 32% from $995K a quarter earlier.
Fund positioning in ZBIO was balanced in Q2 2018: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Virtu Financial, adding an estimated $550K. The largest seller was Jane Street, cutting an estimated $158K.
- 7 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.32M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q2 2018, up 32% quarter-over-quarter.
- 1 fund opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q2 2018 and 1 closed out, a net change of 0 holders.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q2 2018 was Virtu Financial, an estimated $550K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q2 2018 was Jane Street, an estimated $158K sold.
Based on aggregated 13F filings for Q2 2018.